Pi-Gen Pharma Ltd 04387670 false 2024-04-01 2025-03-31 2025-03-31 The principal activity of the company is that of retail pharmacy. Digita Accounts Production Advanced 6.30.9574.0 true false true 04387670 2024-04-01 2025-03-31 04387670 2025-03-31 04387670 bus:Consolidated 2025-03-31 04387670 core:AcceleratedTaxDepreciationDeferredTax 2025-03-31 04387670 core:RetainedEarningsAccumulatedLosses 2025-03-31 04387670 core:ShareCapital 2025-03-31 04387670 core:CurrentFinancialInstruments core:WithinOneYear 2025-03-31 04387670 core:Non-currentFinancialInstruments 2025-03-31 04387670 core:Non-currentFinancialInstruments core:AfterOneYear 2025-03-31 04387670 core:Goodwill 2025-03-31 04387670 core:AdditionsToInvestments 2025-03-31 04387670 core:CostValuation 2025-03-31 04387670 core:DisposalsDecreaseInInvestments 2025-03-31 04387670 core:BetweenTwoFiveYears 2025-03-31 04387670 core:MoreThanFiveYears 2025-03-31 04387670 core:WithinOneYear 2025-03-31 04387670 core:FurnitureFittingsToolsEquipment 2025-03-31 04387670 core:LandBuildings 2025-03-31 04387670 core:MotorVehicles 2025-03-31 04387670 core:EmployeeBenefits 2025-03-31 04387670 bus:SmallEntities 2024-04-01 2025-03-31 04387670 bus:Audited 2024-04-01 2025-03-31 04387670 bus:FilletedAccounts 2024-04-01 2025-03-31 04387670 bus:SmallCompaniesRegimeForAccounts 2024-04-01 2025-03-31 04387670 bus:RegisteredOffice 2024-04-01 2025-03-31 04387670 bus:Director1 2024-04-01 2025-03-31 04387670 bus:Director3 2024-04-01 2025-03-31 04387670 bus:PrivateLimitedCompanyLtd 2024-04-01 2025-03-31 04387670 bus:Agent1 2024-04-01 2025-03-31 04387670 core:Goodwill 2024-04-01 2025-03-31 04387670 core:FurnitureFittingsToolsEquipment 2024-04-01 2025-03-31 04387670 core:LandBuildings 2024-04-01 2025-03-31 04387670 core:MotorVehicles 2024-04-01 2025-03-31 04387670 core:Vehicles 2024-04-01 2025-03-31 04387670 core:EmployeeBenefits 2024-04-01 2025-03-31 04387670 core:OtherRelatedParties 2024-04-01 2025-03-31 04387670 1 2024-04-01 2025-03-31 04387670 countries:EnglandWales 2024-04-01 2025-03-31 04387670 2024-03-31 04387670 core:Goodwill 2024-03-31 04387670 core:FurnitureFittingsToolsEquipment 2024-03-31 04387670 core:LandBuildings 2024-03-31 04387670 core:MotorVehicles 2024-03-31 04387670 core:EmployeeBenefits 2024-03-31 04387670 2023-04-01 2024-03-31 04387670 2024-03-31 04387670 core:AcceleratedTaxDepreciationDeferredTax 2024-03-31 04387670 core:TaxLossesCarry-forwardsDeferredTax 2024-03-31 04387670 core:Non-currentFinancialInstruments 2024-03-31 04387670 core:Non-currentFinancialInstruments core:AfterOneYear 2024-03-31 04387670 core:Goodwill 2024-03-31 04387670 core:BetweenTwoFiveYears 2024-03-31 04387670 core:MoreThanFiveYears 2024-03-31 04387670 core:WithinOneYear 2024-03-31 04387670 core:FurnitureFittingsToolsEquipment 2024-03-31 04387670 core:LandBuildings 2024-03-31 04387670 core:MotorVehicles 2024-03-31 iso4217:GBP xbrli:pure

Registration number: 04387670

Prepared for the registrar

Pi-Gen Pharma Ltd

Annual Report and Financial Statements

for the Year Ended 31 March 2025

 

Pi-Gen Pharma Ltd

Contents

Company Information

1

Balance Sheet

2

Notes to the Financial Statements

3 to 11

 

Pi-Gen Pharma Ltd

Company Information

Directors

K Patel

V Patel

Registered office

109-111 Field End Road
Pinner
HA5 1QG

Auditors

Hazlewoods LLP Staverton Court
Staverton
Cheltenham
GL51 0UX

 

Pi-Gen Pharma Ltd

(Registration number: 04387670)
Balance Sheet as at 31 March 2025

Note

2025
 £

2024
 £

Fixed assets

 

Intangible assets

4

4,515,870

-

Tangible assets

5

1,286,638

110,524

Investments

6

600

-

 

5,803,108

110,524

Current assets

 

Stocks

7

991,858

1,160,275

Debtors

8

3,103,056

3,980,845

Cash at bank and in hand

 

2,040,821

1,155,978

 

6,135,735

6,297,098

Creditors: Amounts falling due within one year

9

(10,968,019)

(6,354,622)

Net current liabilities

 

(4,832,284)

(57,524)

Total assets less current liabilities

 

970,824

53,000

Creditors: Amounts falling due after more than one year

9

(395,000)

-

Provisions

10

(113,615)

-

Deferred tax liabilities

11

(83,400)

(12,128)

Net assets

 

378,809

40,872

Capital and reserves

 

Called up share capital

80

80

Profit and loss account

378,729

40,792

Total equity

 

378,809

40,872

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 16 December 2025 and signed on its behalf by:
 


V Patel
Director

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

 

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
109-111 Field End Road
Pinner
HA5 1QG
England

 

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except for, where disclosed in these accounting policies, certain items that are shown at fair value.

The presentational currency of the financial statements is Pounds Sterling, being the functional currency of the primary economic environment in which the company operates. Monetary amounts in these financial statements are rounded to the nearest Pound.

Summary of disclosure exemptions

The company has taken advantage of the exemption in section 398 of the Companies Act 2006 from the requirement to prepare consolidated financial statements, on the grounds that it is a small group.

Name of parent of group

These financial statements are consolidated in the financial statements of Enimed Holdings Limited.

The financial statements of Enimed Holdings Limited may be obtained from the company's registered office.

Going concern

After reviewing the company's forecasts and projections, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.

Critical accounting judgements and key sources of estimation uncertainty
In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.
 

Judgements

No significant judgements have been made by management in preparing these financial statements.

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

Key sources of estimation uncertainty

No key sources of estimation uncertainty have been identified by management in preparing these financial statements other than those detailed in these accounting policies.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts and after eliminating sales within the company.

The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and when specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a charge attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred income tax is recognised on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred income tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Freehold property

2% straight line

Fixtures, fittings and equipment

15% reducing balance

Motor vehicles

15% reducing balance

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

Goodwill

Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

Intangible assets

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the
company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity
recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently
measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the
currency of the acquired entity and revalued to the closing rate at each reporting period date.

Negative goodwill arising on an acquisition is recognised on the face of the balance sheet on the acquisition date
and subsequently the excess up to the fair value of non-monetary assets acquired is recognised in profit or loss
in the periods in which the non-monetary assets are recovered.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Straight line over 20 years

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Trade debtors

Trade debtors are amounts due from customers for good sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. All trade debtors are repayable within one year and hence are included at the undiscounted cost of cash expected to be received. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the debtors.

Stocks

Stock is valued at the lower of cost and net realisable value, after due regard for obsolete and slow moving stocks. Cost is determined using the first-in, first-out (FIFO) method. Net realisable value is based on selling price less anticipated selling costs. Costs include all direct costs and an appropriate portion of fixed and variable overheads.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of
business from suppliers. Accounts payable are classified as current liabilities if the company does not have an
unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and all are repayable within one year and hence are included at the undiscounted amount of cash expected to be paid.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

Provisions

Provisions are recognised when the company has an obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

Financial instruments


Classification
Financial instruments are classified and accounted for according to the substance of the contractual arrangement, as financial assets, financial liabilities or equity instruments. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities. Where shares are issued, any component that creates a financial liability of the company is presented as a liability on the balance sheet. The corresponding dividends relating to the liability component are charged as interest expenses in the profit and loss account.


Recognition and measurement
All financial assets and liabilities are initially measured at transaction price (including transaction costs), except for those financial assets classified as at fair value through profit or loss, which are initially measured at fair value (which is normally the transaction price excluding transaction costs), unless the arrangement constitutes a financing transaction. If an arrangement constitutes a financing transaction, the financial asset or financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

Impairment

Assets, other than those measured at fair value, are assessed for indicators of impairment at each balance sheet date. If there is objective evidence of impairment, an impairment loss is recognised in the profit and loss as described below.

A non financial asset is impaired where there is objective evidence that, as a result of one or more events that occurred after initial recognition, the estimated recoverable vale of the asset has been reduced. The recoverable amount of an asset is the higher of its fair value less costs to sell and its value in use.

Where indicators exist for a decrease in impairment loss, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised. Where a reversal of impairment occurs in respect of a CGU, the reversal is applied first to the asset's(other than goodwill) of the CGU on a pro-rata basis and then to any goodwill allocated to that CGU.

For financial assets carried at amortised cost, the amount of an impairment is the difference between the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original effective interest rate.

For financial assets carried at cost less impairment, the impairment loss is the difference between the asset’s carrying amount and the best estimate of the amount that would be received for the asset if it were to be sold at the reporting date.

Where indicators exist for a decrease in impairment loss, and the decrease can be related objectively to an event occurring after the impairment was recognised, the prior impairment loss is tested to determine reversal. An impairment loss is reversed on an individual impaired financial asset to the extent that the revised recoverable value does not lead to a revised carrying amount higher than the carrying value had no impairment been recognised.
 

 

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 105 (2024 - 30).

 

4

Intangible assets

Goodwill
 £

Cost

At 1 April 2024

-

Additions

4,993,563

Disposals

(415,083)

At 31 March 2025

4,578,480

Amortisation

At 1 April 2024

-

Amortisation charge

62,610

At 31 March 2025

62,610

Carrying amount

At 31 March 2025

4,515,870

At 31 March 2024

-

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

 

5

Tangible assets

Land and buildings
£

Fixtures, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost

At 1 April 2024

-

112,194

-

112,194

Additions

2,210,066

255,092

23,600

2,488,758

Disposals

(1,262,582)

(5,471)

(4,000)

(1,272,053)

At 31 March 2025

947,484

361,815

19,600

1,328,899

Depreciation

At 1 April 2024

-

1,670

-

1,670

Charge for the year

6,313

33,420

1,125

40,858

Eliminated on disposal

-

(267)

-

(267)

At 31 March 2025

6,313

34,823

1,125

42,261

Carrying amount

At 31 March 2025

941,171

326,992

18,475

1,286,638

At 31 March 2024

-

110,524

-

110,524

Included within the net book value of land and buildings above is £941,171 (2024 - £Nil) in respect of freehold land and buildings and £Nil (2024 - £Nil) in respect of long leasehold land and buildings.
 

 

6

Investments

2025
£

2024
£

Investments in subsidiaries

600

-

Subsidiaries

£

Cost

Additions

800

Disposals

(200)

At 31 March 2025

600

Carrying amount

At 31 March 2025

600

 

7

Stocks

2025
£

2024
£

Medicines and retail stocks

991,858

1,160,275

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

 

8

Debtors

2025
 £

2024
 £

Trade debtors

1,361,458

1,461,338

Other debtors

1,527,105

1,955,102

Prepayments

214,493

564,405

 

3,103,056

3,980,845

 

9

Creditors

2025
 £

2024
 £

Due within one year

Trade creditors

1,360,398

2,702,153

Amounts due to related parties

5,698,836

3,368,385

Social security and other taxes

46,831

140,479

Outstanding defined contribution pension costs

13,541

36,824

Other creditors

3,486,363

-

Accrued expenses

277,098

106,781

Corporation tax liability

84,952

-

10,968,019

6,354,622

Note

2025
£

2024
£

Due after one year

 

Loans and borrowings

12

395,000

-

 

10

Provisions

NHS Reimbursement
£

Total
£

At 1 April 2024

-

-

New provisions

113,615

113,615

At 31 March 2025

113,615

113,615

The NHS reimbursement provision is to cover clawback of potential over-reimbursement received in the current financial year, which will be clawed back over the next 12 months via adjustment through Category M medicines.

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

 

11

Deferred tax

Deferred tax assets and liabilities

2025

Liability
£

Capital allowances in excess of depreciation

83,400

83,400

2024

Liability
£

Capital allowances in excess of depreciation

26,727

Tax losses carried forward

(14,599)

12,128

 

12

Loans and borrowings

Non-current loans and borrowings

2025
£

2024
£

Bank borrowings

395,000

-

Bank loans are secured over the freehold property of the company.

 

13

Obligations under leases

Operating leases

The total of future minimum lease payments is as follows:

2025
£

2024
£

Not later than one year

303,625

-

Later than one year and not later than five years

1,144,500

-

Later than five years

2,550,756

-

3,998,881

-

The amount of non-cancellable operating lease payments recognised as an expense during the year was £425,424 (2024 - £Nil).

 

14

Related party transactions

Summary of transactions with other related parties


During the year, the company received funds from the parent company, Enimed Limited of £1,129,851 (2024 - £1,648,385). As at the year end, the amount owed to the parent company was £2,778,236 (2024 -£1,648,385). There are no fixed repayment terms and no interest is charged on the loan.

During the year the company received funds from entities owning participating interests of £1,200,000 (2024 - £1,720,000). As at the year end, the amount owed to the entities owning participating interests was £2,920,000 (2024 £1,720,000). There are no fixed repayment terms and no interest is charged on the loan.

 

 

Pi-Gen Pharma Ltd

Notes to the Financial Statements for the Year Ended 31 March 2025

 

15

Parent and ultimate parent undertaking

The company's immediate parent is Enimed Limited, incorporated in England & Wales.

 The ultimate parent is Enimed (Holdings) Limited, incorporated in England & Wales. Enimed (Holdings) Limited prepares consolidated financial statements including the company, copies of which can be obtained from its registered office of 109-111 Field End Road, Eastcote, Middlesex, HA15 1QG.

The ultimate controlling party is Mr V Patel.

 

16

Non adjusting events after the financial period

The company sold 7 branches for a total consideration of £2.9m and acquired two freehold properties from which the pharmacies trade for £1.2m.

 

17

Audit report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 16 December 2025 was Julian Gaskell, who signed for and on behalf of Hazlewoods LLP.